The US FDA approval of bedaquiline is historic, as it marks the first drug in a new class approved to combat TB, and specifically MDR-TB, in more than...
Tuberculosis (TB) is a major cause of illness and death among children in low- and middle-income countries, but the current TB drug regimens to treat ...
Even though it’s preventable and treatable, tuberculosis (TB) is a top ten killer of children worldwide. Today, the ACTION Partnership releases...
NEW YORK, NY/GENEVA, SWITZERLAND – A new partnership announced today will increase efforts to coordinate the development of complementary novel ...
“The World Health Organization’s Global Tuberculosis Report 2012 shows that the overall outlook for tuberculosis is improving, alb...
As partners of the Critical Path to TB Drug Regimens (CPTR) initiative prepare to gather for their annual meeting, the members of one of the initiat...
PARIS AND NEW YORK, September 20, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) and the Global Alliance for TB Drug Development (TB Alliance) announced ...
The TB Alliance and its partners will be presenting recent advances in TB research and development at the ICAAC 2012 conference. Posters and presentat...
WASHINGTON, DC/LONDON (July 23, 2012) – A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hu...
The US House of Representatives TB Elimination Caucus and the Congressional HIV/AIDS Caucus invite you to join us for a briefing TB/HIV: New...
Press Contact: press@tballiance.org
Falling Short: Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis
New TB Regimens: What Countries Want
Pathway to Patients
Policy on the Compassionate / Emergency Use of Experimental TB Alliance Drugs